Drug-resistant staph infections continue to be deadlier than those that are not resistant and treatable with traditional antibiotics, but treatment costs surprisingly are the same or slightly less, a new national analysis shows.
Drug-resistant staph infections continue to be deadlier than those that are not resistant and treatable with traditional antibiotics, but treatment costs surprisingly are the same or slightly less, a new national analysis shows.